Lauroyl-gemcitabine lipid nanocapsules (GemC 12 -LNC) hydrogel, administered intratumorally or perisurgically in the tumor resection cavity, increases animal survival in several orthotopic GBM models. We hypothesized that GemC 12 -LNC can be used as nanodelivery platform for other drugs, to obtain a combined local therapeutic approach for GBM. Paclitaxel (PTX) was selected as a model molecule and PTX-GemC 12 -LNC formulation was evaluated in terms of physicochemical and mechanical properties. The PTX-GemC 12 -LNC hydrogel stability and drug release were evaluated over time showing no significant differences compared to GemC 12 -LNC. The drug combination was evaluated on several GBM cell lines showing increased cytotoxic activity compared to the original formulation and synergy between PTX and GemC 12 . Our results suggest that GemC 12 -LNC hydrogel can be used as nanodelivery platform for dual drug delivery to encapsulate active agents with different mechanisms of action to achieve a better antitumor efficacy against GBM or other solid tumors.

Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment

Bastiancich C.
Co-first
;
2019-01-01

Abstract

Lauroyl-gemcitabine lipid nanocapsules (GemC 12 -LNC) hydrogel, administered intratumorally or perisurgically in the tumor resection cavity, increases animal survival in several orthotopic GBM models. We hypothesized that GemC 12 -LNC can be used as nanodelivery platform for other drugs, to obtain a combined local therapeutic approach for GBM. Paclitaxel (PTX) was selected as a model molecule and PTX-GemC 12 -LNC formulation was evaluated in terms of physicochemical and mechanical properties. The PTX-GemC 12 -LNC hydrogel stability and drug release were evaluated over time showing no significant differences compared to GemC 12 -LNC. The drug combination was evaluated on several GBM cell lines showing increased cytotoxic activity compared to the original formulation and synergy between PTX and GemC 12 . Our results suggest that GemC 12 -LNC hydrogel can be used as nanodelivery platform for dual drug delivery to encapsulate active agents with different mechanisms of action to achieve a better antitumor efficacy against GBM or other solid tumors.
559
220
227
Gemcitabine; Glioblastoma; Hydrogel; Local delivery; Nanomedicine; Paclitaxel
Bastiancich C.; Bozzato E.; Luyten U.; Danhier F.; Bastiat G.; Preat V.
File in questo prodotto:
File Dimensione Formato  
Bastiancich et al. Int J Pharm 2019.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.28 MB
Formato Adobe PDF
1.28 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1879912
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 30
social impact